Register for our free email digests:
Latest From St. Jude Children's Research Hospital
Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.
Biotech start-ups cut deals at a rapid pace in 2015, signing almost twice the number of alliances done in 2014. Regenerative medicine was prominent in key partnerships.
In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.
Celgene is staking a leadership claim in immuno-oncology through a broad, 10-year collaboration with one of the leading CAR-T developers, Juno Therapeutics.
Drug Discovery Tools
- Molecular Diversity
- Synthesis Technologies, Production Processes
- Drug Discovery Tools
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- RheoGene Inc.
- Genomatix Ltd.
- North America
- Parent & Subsidiaries
- Intrexon Corp.
- Senior Management
Randal J Kirk, Chmn. & CEO
Rick Sterling, CFO
Thomas D Reed, PhD, CSO
Andrew J Last, COO
- Contact Info
Phone: (301) 556-9900
20358 Seneca Meadows Parkway
Germantown, MD 20876
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.